Truveta valuation, funding and investors
Truveta works in electronic health record data distribution, based in Bellevue, United States. Founded in 2020, it has about 474 employees.
- Last round
- Series C · $320M · Jan 2025
- Valuation at last round
- $1.00B
- Headcount
- 474 · up
- Grade
- B
- Founded
- 2020
Truveta valuation today
VCMC values Truveta at $1.4B today, with a range of $834M to $1.6B and a grade of B. The valuation starts from its last funding round, a Series C round in Jan 2025.
Valuation by date (85 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2020 | $15.1M | $5.49M – $41.4M | $16.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2020 | $15.2M | $5.54M – $41.8M | $16.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2020 | $15.3M | $5.59M – $42.1M | $17.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2020 | $15.5M | $5.64M – $42.5M | $17.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2020 | $15.6M | $5.69M – $42.9M | $17.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2020 | $15.8M | $5.74M – $43.3M | $17.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jul 2020 | $15.9M | $5.79M – $43.7M | $17.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2020 | $16.1M | $5.84M – $44.1M | $17.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2020 | $16.2M | $5.90M – $44.5M | $18.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2020 | $16.3M | $5.95M – $44.9M | $18.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2020 | $16.5M | $6.00M – $45.3M | $18.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2020 | $16.6M | $6.06M – $45.7M | $18.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2021 | $16.8M | $6.11M – $46.1M | $18.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2021 | $16.9M | $6.17M – $46.5M | $18.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2021 | $17.1M | $6.22M – $46.9M | $19.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2021 | $17.2M | $6.28M – $47.4M | $19.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2021 | $17.4M | $6.33M – $47.8M | $19.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2021 | $17.6M | $6.39M – $48.2M | $19.4M (+10%) | before first round | – | unknown | D | 0% |
| 1 Jul 2021 | $17.7M | $6.45M – $48.6M | $19.5M (+10%) | before first round | – | unknown | D | 0% |
| 14 Jul 2021 | $529M | $347M – $1.4B | $950M (+80%) | after a round | – | unknown | C | 0% |
| 1 Aug 2021 | $544M | $347M – $1.4B | $950M (+75%) | after a round | – | unknown | C | 0% |
| 1 Sep 2021 | $572M | $347M – $1.4B | $950M (+66%) | after a round | – | unknown | C | 0% |
| 1 Oct 2021 | $600M | $347M – $1.4B | $950M (+58%) | after a round | – | unknown | C | 0% |
| 1 Nov 2021 | $631M | $347M – $1.4B | $950M (+51%) | after a round | – | unknown | C | 0% |
| 1 Dec 2021 | $662M | $347M – $1.4B | $950M (+43%) | after a round | – | unknown | C | 0% |
| 1 Jan 2022 | $696M | $347M – $1.4B | $950M (+36%) | after a round | – | unknown | C | 0% |
| 1 Feb 2022 | $732M | $347M – $1.4B | $950M (+30%) | after a round | 150 | unknown | C | 0% |
| 1 Mar 2022 | $765M | $347M – $1.4B | $950M (+24%) | after a round | 150 | unknown | C | 0% |
| 1 Apr 2022 | $805M | $347M – $1.4B | $950M (+18%) | after a round | 150 | unknown | C | 0% |
| 1 May 2022 | $844M | $347M – $1.4B | $950M (+13%) | after a round | 150 | unknown | C | 0% |
| 1 Jun 2022 | $888M | $347M – $1.4B | $950M (+7%) | after a round | 150 | unknown | C | 0% |
| 1 Jul 2022 | $931M | $347M – $1.4B | $950M (+2%) | after a round | 150 | unknown | C | 0% |
| 1 Aug 2022 | $950M | $336M – $1.4B | $950M (0%) | after a round | 150 | unknown | C | 0% |
| 1 Sep 2022 | $950M | $320M – $1.4B | $950M (0%) | after a round | 150 | unknown | C | 0% |
| 1 Oct 2022 | $950M | $304M – $1.4B | $950M (0%) | after a round | 150 | unknown | C | 0% |
| 1 Nov 2022 | $950M | $289M – $1.4B | $950M (0%) | after a round | 150 | unknown | C | 0% |
| 1 Dec 2022 | $950M | $275M – $1.4B | $950M (0%) | after a round | 150 | unknown | C | 0% |
| 1 Jan 2023 | $950M | $375M – $1.4B | $950M (0%) | after a round | 240 | growing | C | 0% |
| 1 Feb 2023 | $950M | $381M – $1.4B | $950M (0%) | after a round | 240 | growing | C | 0% |
| 1 Mar 2023 | $950M | $386M – $1.4B | $950M (0%) | after a round | 240 | growing | C | 0% |
| 1 Apr 2023 | $950M | $391M – $1.4B | $950M (0%) | after a round | 240 | growing | C | 0% |
| 1 May 2023 | $950M | $397M – $1.4B | $950M (0%) | after a round | 240 | growing | C | 0% |
| 1 Jun 2023 | $950M | $403M – $1.4B | $950M (0%) | after a round | 240 | growing | C | 0% |
| 1 Jul 2023 | $950M | $408M – $1.4B | $950M (0%) | after a round | 240 | growing | C | 0% |
| 1 Aug 2023 | $950M | $354M – $1.4B | $950M (0%) | after a round | 240 | growing | C | 0% |
| 1 Sep 2023 | $950M | $175M – $1.4B | $950M (0%) | after a round | 240 | unknown | D | 0% |
| 1 Oct 2023 | $950M | $167M – $1.4B | $950M (0%) | after a round | 240 | unknown | D | 0% |
| 1 Nov 2023 | $950M | $159M – $1.4B | $950M (0%) | after a round | 240 | unknown | D | 0% |
| 1 Dec 2023 | $950M | $151M – $1.4B | $950M (0%) | after a round | 240 | unknown | D | 0% |
| 1 Jan 2024 | $950M | $144M – $1.4B | $950M (0%) | after a round | 240 | unknown | D | 0% |
| 1 Feb 2024 | $950M | $136M – $1.4B | $950M (0%) | after a round | 240 | unknown | D | 0% |
| 1 Mar 2024 | $950M | $192M – $1.4B | $941M (-1%) | after a round | 310 | up | D | 0% |
| 1 Apr 2024 | $950M | $186M – $1.4B | $940M (-1%) | after a round | 310 | up | D | 0% |
| 1 May 2024 | $950M | $181M – $1.4B | $939M (-1%) | after a round | 310 | up | D | 0% |
| 1 Jun 2024 | $950M | $176M – $1.4B | $938M (-1%) | after a round | 310 | up | D | 0% |
| 1 Jul 2024 | $950M | $170M – $1.4B | $937M (-1%) | after a round | 310 | up | D | 0% |
| 1 Aug 2024 | $946M | $101M – $1.4B | $874M (-8%) | after a round | 330 | flat | D | 0% |
| 1 Sep 2024 | $940M | $96.2M – $1.4B | $868M (-8%) | after a round | 330 | flat | D | 0% |
| 1 Oct 2024 | $934M | $91.5M – $1.4B | $863M (-8%) | after a round | 330 | flat | D | 0% |
| 1 Nov 2024 | $928M | $87.0M – $1.4B | $858M (-7%) | after a round | 330 | flat | D | 0% |
| 1 Dec 2024 | $922M | $82.8M – $1.4B | $853M (-7%) | after a round | 330 | flat | D | 0% |
| 1 Jan 2025 | $916M | $78.7M – $1.4B | $847M (-7%) | after a round | 330 | flat | D | 0% |
| 14 Jan 2025 | $1.0B | $869M – $1.5B | $1.3B (+30%) | after a round | 330 | flat | A | 0% |
| 1 Feb 2025 | $1.0B | $869M – $1.5B | $1.3B (+28%) | after a round | 330 | flat | A | 0% |
| 1 Mar 2025 | $1.0B | $869M – $1.5B | $1.3B (+26%) | after a round | 330 | flat | A | 0% |
| 1 Apr 2025 | $1.1B | $869M – $1.5B | $1.3B (+23%) | after a round | 330 | flat | A | 0% |
| 1 May 2025 | $1.1B | $869M – $1.5B | $1.3B (+20%) | after a round | 330 | flat | A | 0% |
| 1 Jun 2025 | $1.1B | $869M – $1.5B | $1.3B (+18%) | after a round | 330 | flat | A | 0% |
| 1 Jul 2025 | $1.1B | $869M – $1.5B | $1.3B (+15%) | after a round | 330 | flat | A | 0% |
| 1 Aug 2025 | $1.2B | $869M – $1.5B | $1.3B (+14%) | after a round | 379 | up | A | 0% |
| 1 Sep 2025 | $1.2B | $869M – $1.5B | $1.3B (+11%) | after a round | 379 | up | A | 0% |
| 1 Oct 2025 | $1.2B | $869M – $1.6B | $1.3B (+9%) | after a round | 391 | up | A | 0% |
| 1 Nov 2025 | $1.3B | $869M – $1.6B | $1.3B (+6%) | after a round | 391 | up | A | 0% |
| 1 Dec 2025 | $1.3B | $869M – $1.6B | $1.3B (+4%) | after a round | 391 | up | A | 0% |
| 1 Jan 2026 | $1.3B | $869M – $1.6B | $1.4B (+1%) | after a round | 402 | up | A | 0% |
| 1 Feb 2026 | $1.4B | $865M – $1.6B | $1.4B (0%) | after a round | 402 | up | A | 0% |
| 1 Mar 2026 | $1.4B | $859M – $1.6B | $1.4B (0%) | after a round | 402 | up | A | 0% |
| 1 Apr 2026 | $1.4B | $853M – $1.6B | $1.4B (0%) | after a round | 402 | up | B | 0% |
| 1 May 2026 | $1.4B | $851M – $1.6B | $1.4B (0%) | after a round | 434 | up | B | 0% |
| 1 Jun 2026 | $1.4B | $846M – $1.6B | $1.4B (0%) | after a round | 434 | up | B | 0% |
| 1 Jul 2026 | $1.4B | $841M – $1.6B | $1.4B (0%) | after a round | 434 | up | B | 0% |
| 1 Aug 2026 | $1.4B | $838M – $1.6B | $1.4B (0%) | after a round | 446 | up | B | 0% |
| 1 Sep 2026 | $1.4B | $834M – $1.6B | $1.4B (0%) | after a round | 446 | up | B | 0% |
| 1 Oct 2026 | $1.4B | $837M – $1.6B | $1.4B (0%) | after a round | 474 | up | B | 0% |
| 24 Oct 2026 | $1.4B | $834M – $1.6B | $1.4B (0%) | after a round | 474 | up | B | 0% |
Key facts about Truveta
- Founded
- 2020
- Headquarters
- Bellevue, United States
- Employees
- about 474 +21% in a year
- Total raised
- $415M
- Funding rounds
- 2
- Last round
- Series C Jan 2025
Truveta was founded in 2020 by Jay Nanduri, Ryan Ahern and Terry Myerson.
Truveta funding history
Truveta has 2 funding rounds on record, from Jul 2021 to Jan 2025, $415M in total. The latest disclosed valuation is $1.00B post-money (Series C, Jan 2025).
Series C 13 Jan 2025
With Regeneron, Illumina Ventures, Providence Health & Services, Trinity Capital, Advocate Health, CommonSpirit Health, Henry Ford Health, Northwell Health, Providence Equity, 17 health systems, Regeneron Pharmaceuticals.
Sources: itspronounceddata.beehiiv.com, cervicornconsulting.com
$320M
$1.00B post-money
Series A 13 Jul 2021
With Baylor Scott & White Health, MedStar Health, Texas Health Resources, Providence Equity, Advocate Aurora Health, Trinity Capital, Tenet Healthcare, Northwell Health, Advent International, Baptist Health of Northeast Florida, Bon Secours Mercy Health, CommonSpirit Health, Hawaii Pacific Health, Henry Ford Health System, Memorial Hermann Health System, Novant Health, Sentara Healthcare.
Sources: globenewswire.com, truveta.com, statnews.com and 3 more
$95M
Truveta investors
24 investors have backed Truveta.
- CommonSpirit Health 2 rounds
- Northwell Health 2 rounds
- 17 health systems
- Advent International
- Advocate Aurora Health
- Advocate Health
- Baptist Health of Northeast Florida
- Baylor Scott & White Health
- Bon Secours Mercy Health
- Hawaii Pacific Health
- Henry Ford Health
- Henry Ford Health System
- MedStar Health
- Memorial Hermann Health System
- Novant Health
- Providence Health & Services
- Regeneron
- Regeneron Pharmaceuticals
- Sentara Healthcare
- Tenet Healthcare
- Texas Health Resources
What Truveta does
Truveta works in tech companies, with 14 recorded offerings and customers in healthcare, life sciences and public health.
Truveta Inc. is an American health data and analytics company that provides regulatory-grade safety and effectiveness data solutions based on real-world electronic health record (EHR) data. The company offers a platform for clinical notes, images, and genomics data, supporting therapy development, care quality improvement, and public health initiatives. Truveta also operates as a software provider, offering a research platform and a language model to facilitate data analysis and research. Its clients include life science, public health, healthcare, and academic research organizations, and the company is supported by a network of U.S. health systems that provide governance and strategic guidance.
Description from Veridion's company data.
Products and services
- Electronic Health Record Data Distribution
- Clinical Notes and Imaging Data Distribution
- Genomics Data Distribution
- Regulatory-Grade Data Solutions
- Healthcare Data Analytics Services
- Clinical Trial Data Support Services
- Therapy Development Data Solutions
- Public Health Data Solutions
- Healthcare Innovation Research Services
- Genomics Database Development
- Actionable Healthcare Insights Generation
- Patient Care Improvement Solutions
- Healthcare Data Quality Assurance Services
- Healthcare Data Privacy and Security Services
Markets
- Healthcare
- Life Sciences
- Public Health
Technology
- Language Model for Healthcare Data Analysis
- Genomics Data Integration for Healthcare Research
- Real-World Electronic Health Record Data Analytics
Business model
- Business-to-Business
- Software-as-a-Service
- Enterprise
Industry codes (NAICS)
- 513210 Software Publishers 70% match
- 518210 Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services 30% match
Questions about Truveta
What is Truveta worth?
Valuation $1.4B (range $834M to $1.6B), as of 24 Oct 2026. The last disclosed valuation was $1.00B (Series C, Jan 2025).
Has Truveta raised money?
Truveta has 2 funding rounds on record, from Jul 2021 to Jan 2025, $415M in total. The latest disclosed valuation is $1.00B post-money (Series C, Jan 2025).
Who has invested in Truveta?
CommonSpirit Health, Northwell Health, Providence Equity, Trinity Capital, 17 health systems and Advent International, and 18 more.
How many people work at Truveta?
About 474, up 21% over the last year. Headcount grew from 150 in Feb 2022 to 474 in Sep 2026.
What does Truveta do?
Truveta works in tech companies, with 14 recorded offerings and customers in healthcare, life sciences and public health. Its main offerings are electronic health record data distribution, clinical notes and imaging data distribution and genomics data distribution.
When was Truveta founded, and where is it based?
Truveta was founded in 2020 and is based in Bellevue, United States. It has about 474 employees, up 21% over the last year.